As expected, the downregulated phosphorylation levels of ERK1/2 induced by osimertinib in GBM cells were robustly reversed by TRIP13 overexpression in LN-229 cells (Fig. 4D), whereas enhanced by TRIP13 depletion in U87MG cells (Fig. 4E). This evidence concerns the gene MAPK3 and glioblastoma.